We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

47 hedge funds and large institutions have $27.7M invested in Matinas BioPharma in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.09% less ownership

Funds ownership: 0.54% → 0.45% (-0.09%)

13% less funds holding

Funds holding: 54 → 47 (-7)

33% less capital invested

Capital invested by funds: $41.1M → $27.7M (-$13.4M)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Holders
47
Holders Change
-7
Holders Change %
-12.96%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
13
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.36M
2
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
+$192K
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$94.7K
4
Wells Fargo
Wells Fargo
California
+$74.2K
5
Northern Trust
Northern Trust
Illinois
+$52.7K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$1.88M
2
SCM
Stonepine Capital Management
Oregon
-$1.29M
3
JGC
J. Goldman & Co
New York
-$1.14M
4
CH
CVI Holdings
Delaware
-$991K
5
Millennium Management
Millennium Management
New York
-$382K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$31K – – –
JMPWA
27
JP Morgan Private Wealth Advisors
California
$26K – – –
VF
28
Virtu Financial
New York
$25K -$83.6K -1,739 -75%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$24K -$11.7K -243 -31%
LTFS
30
Ladenburg Thalmann Financial Services
Florida
$21K – – –
AWM
31
AE Wealth Management
Kansas
$17K +$19.2K +399 New
SS
32
Simplicity Solutions
Minnesota
$17K +$19.2K +399 New
NRS
33
Neville Rodie & Shaw
New York
$15K – – –
Commonwealth Equity Services
34
Commonwealth Equity Services
Massachusetts
$14K +$769 +16 +5%
ARTA
35
A.R.T. Advisors
New York
$14K +$15.2K +316 New
RJA
36
Raymond James & Associates
Florida
$11K +$12K +250 New
USAA
37
United Services Automobile Association
Texas
$10K – – –
CFS
38
CRA Financial Services
New Jersey
$9K – – –
FC
39
Fore Capital
New York
$9K – – –
IIA
40
IPG Investment Advisors
California
$8.57K -$31.2K -650 -76%
AG
41
Advisor Group
Arizona
$3K – – –
HFM
42
Hartford Financial Management
Connecticut
$2K – – –
CAL
43
Capital Analysts LLC
Pennsylvania
$1K – – –
Morgan Stanley
44
Morgan Stanley
New York
$1K – – –
APA
45
American Portfolios Advisors
New York
$428 – – –
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$23 – – –
JGC
47
J. Goldman & Co
New York
– -$1.14M -20,900 Closed
CH
48
CVI Holdings
Delaware
– -$991K -18,193 Closed
Renaissance Technologies
49
Renaissance Technologies
New York
– -$276K -5,060 Closed
Deutsche Bank
50
Deutsche Bank
Germany
– -$275K -5,059 Closed
1
2
3

MTNB Hedge Fund Activity: Q2 2019 in Review

47 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2019, worth a combined $27.7M — down 33% from $41.1M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of MTNB and 5 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $1.36M. The largest seller was Broadfin Capital, cutting an estimated $1.88M.

  • 47 institutional investors held Matinas BioPharma (MTNB) as of Q2 2019, down from 54 in Q1 2019.
  • Funds reported $27.7M of Matinas BioPharma stock for Q2 2019, down 33% quarter-over-quarter.
  • 5 funds opened new Matinas BioPharma positions in Q2 2019 and 12 closed out, a net change of -7 holders.
  • The largest Matinas BioPharma buyer in Q2 2019 was Vanguard Group, an estimated $1.36M added.
  • The largest Matinas BioPharma seller in Q2 2019 was Broadfin Capital, an estimated $1.88M sold.

Based on aggregated 13F filings for Q2 2019.